Abnormal and Abilify


Abnormal Symptoms and Causes

The cervix is the lower part of the uterus, the place where a baby grows during pregnancy. Cancer screening is looking for cancer before you have any symptoms. Cancer found early may be easier to treat.

Cervical cancer screening is usually part of a woman's health checkup. There are two types of tests: the Pap test and the HPV test. For both, the doctor or nurse collects cells from the surface of the cervix. With the Pap test, the lab checks the sample for cancer cells or Abnormal cells that could become cancer later. With the HPV test, the lab checks for HPV infection. HPV is a virus that spreads through sexual contact. It can sometimes lead to cancer. If your screening tests are Abnormal, your doctor may do more tests, such as a biopsy.

Cervical cancer screening has risks. The results can sometimes be wrong, and you may have unnecessary follow-up tests. There are also benefits. Screening has been shown to decrease the number of deaths from cervical cancer. You and your doctor should discuss your risk for cervical cancer, the pros and cons of the screening tests, at what age to start being screened, and how often to be screened.

Check out the latest treatments for abnormal

abnormal treatment research studies

Abilify clinical trials, surveys and public health registries

Find Drug Side Effect reports

Abilify Side Effects

Weight Increased (762)
Tremor (544)
Tardive Dyskinesia (527)
Insomnia (486)
Pregnancy (435)
Dyskinesia (400)
Dizziness (324)
Somnolence (323)
Nausea (313)
Restlessness (308)
Headache (296)
Fatigue (289)
Psychotic Disorder (287)
Akathisia (286)
Anxiety (282)
Agitation (257)
Vomiting (254)
Convulsion (243)
Delusion (233)
Blood Glucose Increased (228)
Depression (192)
Dystonia (189)
Feeling Abnormal (188)
Vision Blurred (185)
Suicidal Ideation (179)
Death (178)
Mania (178)
Hallucination (176)
Aggression (174)
Neuroleptic Malignant Syndrome (169)
Fall (169)
Confusional State (167)
Weight Decreased (150)
Extrapyramidal Disorder (140)
Dyspnoea (136)
Hallucination, Auditory (136)
Schizophrenia (135)
Gait Disturbance (135)
Abnormal Behaviour (135)
Muscle Spasms (133)
Suicide Attempt (131)
Loss Of Consciousness (128)
Hyperhidrosis (125)
Musculoskeletal Stiffness (123)
Dysphagia (123)
Asthenia (121)
Blood Creatine Phosphokinase Increased (110)
Oedema Peripheral (109)
Completed Suicide (108)
Irritability (105)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Recent Reviews

dystonia...on the right hand

Abilify for BiPolar Disorder, how does it work for you?

Abilify lifts the cloud of depression for me But - the sweating is profuse -- just dripping if I do any kind of movement

Abilify, lost everything, could'nt stop gambling until I got off of it.

Abilify, side effects ruined my life. I have compulsive bahavior, I gambled I lost everything. I am looking for a good Lawyer. (409) 548-0460.

As human experience is limited, administration of aripiprazole should be used in pregnancy only if the potential benefit to the mother outweighs the potential risk to the foetus.

Can a horseshoe kidney cause diluted drug tests?

Can it cause constipation? My lil was had been bad

Can't sleep any more than 3 to 4 hours at a time anyone else with that problem?

Developed bruxism after starting abilify and lithium

after taking my medicine .i felt abnormal taste in mouth and my bilurubin level was increased.

I took centrum for almost one month.and I notice that my menstruation suddenly became abnormal in short AMENNORHEA....until now iam almost 1 month and 3 days delayed and took pregnancy test but the result was

<strong>I took 2 capsules at 7.20m after having breakfast and started feeling side effects at 8.25am. It started with increased temperature, abnormal levels of perspiration, dizziness and severe nausea. </strong

1100 sinus rhythm 2210 short pr intrval 9150 abnormal**ecg

9150 **abnormal ecg

Abnormal dreams!!!!

Abnormal ear wax after usage and healing from Ciprodex.

After 2 and half months of taking boniva i devoped severe shoulder pain that cause tendonitis and bursitis and abnormal bone formation and will have to have surgery now to inprove my pain i have been in severe pain for 5 months now boniva side eff

Difficult of walking,dizzinese,abnormal behavior

I am 51 taking Livalo for about a year now. My cholesterol numbers are great, and my side effects have been next to nothing. Previous statins were intolerable with pain, overall discomfort. Now - no abnormal aches and pain. I have gained a good bit o

Abnormal Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  The Accuracy of Sentinel Node Biopsy of Breast Cancer With Sonographic Abnormal Axillary Lymph Nodes
Condition: Breast Cancer
Intervention: Procedure: Wire-localized Abnormal node
Outcome Measure: False negative rate of sentinel node biopsy if sonographic Abnormal node not be removed
2 Recruiting Comparison Between Oral Clindamycin Vs Metronidazole for the Treatment of Abnormal Vaginal Flora in High Risk Pregnancies
Conditions: Abnormal Vaginal Flora;   Clindamycin Vs Metronidazole;   High Risk Pregnancies for Preterm Labor
Interventions: Drug: Clindamycin;   Drug: Metronidazole
Outcome Measures: To compare the efficacy between oral Clindamycin Vs Metronidazole in the eradication of Abnormal vaginal flora;   The prevalence of adverse effects;   The prevalence of late abortions and preterm deliveries;   Assessing the correlation between Nugent score , physical examination and Ph indicators
3 Unknown  The Value of Bacterial Loads by Real Time PCR in Predicting Recurrence of Abnormal Vaginal Flora After Oral Metronidazole Therapy
Condition: Abnormal Vaginal Flora
Intervention: Drug: Treatment BY METROMIDAZOLE
Outcome Measures: To access the value of A. vaginae and G. vaginalis loads in predicting recurrence of Abnormal vaginal flora over the course of 12 months after oral metronidazole therapy.;   Inform the predictive and technical characteristics (sensibility and specificity) vaginal microbial concentrations
4 Recruiting Cervical Ripening Before Endometrial Biopsy in Abnormal Uterine Bleeding Using Sublingual Misoprostol
Condition: Abnormal Uterine Bleeding Unrelated to Menstrual Cycle
Interventions: Drug: Misoprostol;   Drug: Vitamin B6
Outcome Measure: efficacy of 200 microgram Misoprostol for cervical ripening prior to performing fractional curettage in patients with Abnormal uterine bleeding
5 Recruiting CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1
Conditions: Abnormal Glucose Tolerance;   Type 1 Diabetes
Interventions: Drug: CTLA4-Ig (Abatacept);   Drug: Placebo
Outcome Measures: Change from Normal Glucose Tolerance to Abnormal Glucose Tolerance;   Change in C-peptide response to Oral Glucose Tolerance Test (OGTT)
6 Not yet recruiting Transvaginal Ultrasound in Women With Abnormal Uterine Bleeding
Condition: Abnormal Uterine Bleeding
Intervention: Device: Transvaginal sonography
Outcome Measures: The accuracy of endometrial thickness and endometrial pattern detected by transvaginal ultrasound in predicting endometrial hyperplasia and endometrial cancer.;   To identify the cut-off points of endometrial thickness that can differentiate normal endometrial pathology and endometrial hyperplasia/endometrial cancer.
7 Recruiting Maternal Genitourinary Infections and Adverse Perinatal Outcomes
Condition: Maternal Infection Affecting Newborn
Intervention: Other: Screening treatment and referral
Outcome Measures: Number of preterm births reduced by community-based screening and treatment of Abnormal vaginal flora and urinary tract infections in early pregnancy (13-19 weeks);   Proportion of early outcomes;   Proportion of infants with neonatal sepsis;   Prevalance Abnormal vaginal flora;   Accuracy of diagnostic tests for detecting bacterial vaginosis
8 Recruiting Abnormal Post-partum Glucose Metabolism After Gestational Diabetes Diagnosed Before or After 24 Weeks of Gestation
Conditions: Gestational Diabetes;   Type 2 Diabetes;   Glucose Intolerance
Intervention: Biological: Post-partum oral glucose tolerance test
Outcome Measures: Presence/absence of Abnormal glucose metabolism;   Presence/absence of type 2 diabetes;   Presence/absence of glucose intolerance;   Presence/absence of impaired fasting glucose;   Patient requiring insulin: yes/no;   Presence/absence of complications;   Baby's weight at birth (kg);   Weeks of amenorrhea (duration of pregnancy in weeks/ gestational age);   Patient was older than 35 years of age at beginning of pregnancy? yes/no;   Body mass index > 25 at beginning of pregnancy? yes/no;   First degree family history of type 2 diabetes? yes/no;   History of gestational diabetes? yes/no;   History of macrosomia? yes/no;   Fasting glucose (g/l);   Oral glucose tolerance test results if necessary
9 Recruiting Effects of Abnormal Respiratory Mechanics and Assisted Mechanical Ventilation on Neuro-regulation of Respiration
Condition: Neuroregulation of Breathing
Intervention: Procedure: Records of EADI derived parameters
Outcome Measures: Eadi-time curve;   Gastric pressure-time curve;   Oesophageal pressure-time curve;   Pressure-time curve
10 Recruiting Inflammatory Responses in Normal Volunteers and Patients With Abnormal Immune Responses
Conditions: Healthy;   Inflammation;   Vasculitis
Outcome Measure:
11 Recruiting Efficacy of Diclofenac on Pain During Endometrial Sampling
Condition: Abnormal Uterine Bleeding Unrelated to Menstrual Cycle
Interventions: Drug: Diclofenac Potassium;   Drug: Folic Acid
Outcome Measure: Effectiveness of Diclofenac Potassium for additional acute pain control in patient undergoing fractional curettage under paracervical block due to Abnormal uterine bleeding
12 Not yet recruiting Accuracy of FNA Versus CNB of Abnormal Axillary Lymph Nodes in Setting of Invasive Breast Cancer
Condition: Breast Cancer
Intervention: Procedure: FNA and Core biopsy
Outcome Measures: Accuracy of FNA and CNB;   Pain associated with FNA and CNB
13 Unknown  Safety, Tolerability, PK, and PD of LIM-0705 in Subjects With Impaired Glucose Tolerance or Abnormal HOMA-IR
Conditions: Impaired Glucose Tolerance;   Insulin Resistance
Interventions: Drug: LIM-0705;   Drug: Placebo capsules
Outcome Measures: Evaluate the safety (number of subjects with adverse events) of LIM-0705 administered to adult males and females with impaired glucose tolerance or Abnormal HOMA-IR;   Examine the pharmacokinetics (PK) of LIM-0705 as measured by area under the curve (AUC).;   Explore the pharmacodynamics (PD) of LIM-0705 in obese adult males and females with impaired glucose tolerance or Abnormal HOMA-IR as measured by change in response to hyperinsulinemic clamp, mixed-meal tolerance test (MMTT) between Days -2 and 27;   Explore the effect of LIM-0705 on fasting lipid, insulin and glucose profiles compared to baseline levels;   Evaluate the tolerability (BID) of LIM-0705 administered to adult males and females with impaired glucose tolerance or Abnormal HOMA-IR
14 Recruiting Metabolically Normal and Metabolically Abnormal Obesity
Conditions: Obesity;   Metabolic Syndrome
Intervention: Behavioral: overfeeding
Outcome Measures: Change in Intrahepatic Triglyceride;   Change in de novo lipogenesis;   Change in VLDL kinetics;   Change in hepatic insulin sensitivity;   Change in skeletal muscle insulin sensitivity;   Change in adipose tissue insulin sensitivity;   Change in CD36 concentration in skeletal muscle;   change in CD36 concentration in adipose tissue
15 Unknown  Abnormal Structure and Bone Density in Diabetes
Conditions: Type 1 Diabetes;   Type 2 Diabetes
Interventions: Radiation: Radiography;   Other: Urine and Blood sampling;   Other: Echography
Outcome Measures: evaluate the MicroScanner, alterations quantitative and qualitative bone in the foot in patients with type 1 diabetes 2 with or without neuropathy;   correlation involving bone and extension of neuropathy Assessment criteria associated with biological Abnormalities qualitative and quantitative bone in diabetic subjects
16 Unknown  Anal Dysplasia in Patients With Inflammatory Bowel Disease
Condition: IBD
Intervention: Procedure: Anal Pap Smear, HPV DNA Testing
Outcome Measure: Abnormal anal cytology and presence of high risk HPV DNA
17 Recruiting Aspirin for the Enhancement of Trophoblastic Invasion in Women With Abnormal Uterine Artery Doppler at 11-14 Weeks of Gestation
Condition: Placental Insufficiency
Interventions: Drug: Aspirin;   Drug: placebo
Outcome Measures: Uterine artery mean pulsatility;   Pre-eclampsia;   Severe preeclampsia;   Intrauterine Growth Retardation;   Significant neonatal morbidity;   number of cesarean;   Neonatal acidosis;   Perinatal mortality;   Days in the Neonatal Intensive Care Unit
18 Recruiting Artifact-Free High-Resolution Myocardial Perfusion MRI in Subjects With Abnormal Nuclear Myocardial Perfusion Studies
Conditions: Coronary Artery Disease;   CAD
Interventions: Drug: regadenoson;   Drug: Optimark®;   Device: Myocardial perfusion MRI
Outcome Measure: Presence and severity of perfusion deficit on images
19 Recruiting Investigating Abnormal Lipid Layer Thickness in Blepharoplasty Patients
Condition: Lipid Thickness
Intervention: Device: Tear Science LipiView
Outcome Measures: Lipid layer thickness;   Tear break up time;   Fluorescein Dye Corneal Staining
20 Recruiting Follow-up of Abnormal and Inadequate Smear-test Results
Condition: Carcinoma in Situ of Uterine Cervix
Interventions: Other: Test result sent by letter;   Other: Test result conveyed by general practitioners
Outcome Measures: Proportion of women with timely follow-up;   Frequency of general practitioner contacts (consultations/telephone calls /e-mails) regarding conveying the smear test result.